A head-to-head trial of two widely used TAVR devices in patients with small aortic annuli, mostly women, showed differences in performance at 1 year in the SMART trial.
Survival in patients who underwent the Ross procedure, a technically complex technique to replace the aortic valve, is 83% after 25 years, which matches that of the general population.
Different results from long-term follow-up of the PARTNER-3 and Evolut trials evaluating TAVR vs surgery in low-surgical-risk patients are leading to some interesting discussions.
The Trilogy transcatheter aortic valve replacement system was safe and effective for high-risk surgical patients with aortic regurgitation, improving LV remodeling and function, in the ALIGN-AR trial.